The FDA has approved Lilly’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, or non-fatal stroke in ...

Medicare Advantage enrollees who developed a new complex condition, such as congestive heart failure or Alzheimer’s disease, were more likely to leave their plan for traditional Medicare the next year ...

The FDA has approved Lisraya (brepocitinib) to treat adults with dermatomyositis, rare autoimmune disease. Dermatomyositis ...

University of Maryland researchers used machine learning models trained on claims data of adults with diabetes to predict ...

Eli Lilly’s Zepbound real-world study shows older adults with obesity cut non-drug healthcare costs 25% via fewer hospital and ER visits, informing Medicare coverage.

Shifting focus, there's a lot going on in the individual market — in the ACA [Affordable Care Act] exchange plans — with the end of the enhanced tax credits. There's a flight to high-deductible bronze ...

A large multicenter trial testing intravenous arginine as a treatment for acute pain crises in sickle cell patients has ended ...

A new study from UCLA has found that insurers saw $3,820 lower monthly costs from the use of biosimilars. Cancer patients ...

Margaret A. Murray, M.P.A., CEO of the Association for Community Affiliated Plans, says outreach and texting will be key to keeping eligible Medicaid enrollees covered under new redetermination and ...